Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-46 (canceled)

47 (previously presented): A method of inhibiting the generation of active thrombin on the surface of a cell within an atherosclerotic plaque within a mammal, the method comprising increasing the expression or activity of an ER resident calcium-binding protein in said cell by directly administering to said cell a polynucleotide operably linked to a promoter, wherein said polynucleotide encodes said ER resident calcium-binding protein, and wherein said ER resident calcium-binding protein is a member selected from the group consisting of GRP78/BiP, GRP94, GRP72, Calreticulin, Calnexin, Reticulocalbin, and Protein disulfide isomerase, whereby said ER resident calcium-binding protein is produced in said cell and the generation of active thrombin on the surface of said cell is inhibited.

48 (previously presented): The method of claim 47, wherein said cell is an endothelial cell.

49 (previously presented): The method of claim 47, wherein said cell is a smooth muscle cell.

50 (previously presented): The method of claim 47, wherein said cell is a macrophage.

51 (previously presented): The method of claim 47, wherein said cell is a monocyte.

52 (previously presented): The method of claim 47, wherein said ER resident calcium-binding protein is GRP78/BiP.

53 (previously presented): The method of claim 47, wherein said ER resident calcium-binding protein is selected from the group consisting of GRP94, GRP72, Calreticulin, Calnexin, Reticulocalbin and Protein disulfide isomerase.

54 (previously presented): The method of claim 47, wherein the increase in the expression or activity of said ER resident calcium-binding protein within said cell results in a decrease in the level of tissue factor procoagulant activity on the surface of said cell.

55 (canceled)

56 (previously presented): The method of claim 47, wherein said polynucleotide is introduced into said cell using a viral vector.

57 (previously presented): The method of claim 56, wherein said viral vector is an adenoviral vector.

58 (previously presented): The method of claim 47, wherein said polynucleotide is introduced into said cell using a nonviral vector.

59 (previously presented): The method of claim 58, wherein said nonviral vector is introduced into said cell as naked DNA or using liposome-mediated transfection.

60-67 (canceled)